Cargando…

Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models()()

Resistance to chemotherapy remains a major challenge in the treatment of human glioblastoma (GBM). Glycogen synthase kinase-3β (GSK-3β), a positive regulator of NF-κB–mediated survival and chemoresistance of cancer cells, has been identified as a potential therapeutic target in human GBM. Our object...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ugolkov, Andrey, Qiang, Wenan, Bondarenko, Gennadiy, Procissi, Daniel, Gaisina, Irina, James, C. David, Chandler, James, Kozikowski, Alan, Gunosewoyo, Hendra, O'Halloran, Thomas, Raizer, Jeffrey, Mazar, Andrew P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2017
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496477/ https://www.ncbi.nlm.nih.gov/pubmed/28672195 http://dx.doi.org/10.1016/j.tranon.2017.06.003

Ejemplares similares

9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer
por: Kuroki, Hiroo, et al.
Publicado: (2019)

Clinically relevant GSK-3β inhibitor 9-ING-41 is active as a single agent and in combination with other antitumor therapies in human renal cancer
por: Anraku, Tsutomu, et al.
Publicado: (2020)

GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents
por: Karmali, Reem, et al.
Publicado: (2017)

9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells
por: Poloznikov, Andrey, et al.
Publicado: (2021)

Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic Tumors()
por: Bondarenko, Gennadiy, et al.
Publicado: (2015)

Chemopotentiation of CCNU metabolites by misonidazole.
por: Mulcahy, R. T.
Publicado: (1985)

GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties
por: Park, Robin, et al.
Publicado: (2021)

Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition
por: Coats, Josh T., et al.
Publicado: (2023)

Chemosensitization by misonidazole in CCNU-treated spheroids and tumours.
por: Durand, R. E., et al.
Publicado: (1987)

In vivo combination of misonidazole and the chemotherapeutic agent CCNU.
por: Siemann, D. W.
Publicado: (1981)

Cisplatin and CCNU synergism in spheroid cell subpopulations.
por: Durand, R. E.
Publicado: (1990)

Procarbazine, CCNU, and Vincristine Chemotherapy in Gliomatosis Cerebri
por: Lee, Hyun Gon, et al.
Publicado: (2014)

Aberrant expression of glycogen synthase kinase-3β in human breast and head and neck cancer
por: Ugolkov, Andrey V., et al.
Publicado: (2018)

Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.
por: Hirst, D. G., et al.
Publicado: (1982)

Response of two mouse tumours to hyperthermia with CCNU or melphalan.
por: Joiner, M. C., et al.
Publicado: (1982)

Priming with low doses of methyl-CCNU reduce the toxicity of high doses of methyl-CCNU and melphalan, and increase the lifespan of mice implanted with Lewis lung carcinoma.
por: Zimber, A., et al.
Publicado: (1988)

Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation
por: Kim, Se-Hyuk, et al.
Publicado: (2018)

Editorial: Antimycobacterial drug discovery: Molecular therapeutics and target identification
por: Gunosewoyo, Hendra, et al.
Publicado: (2022)

Editorial: Antimycobacterial drug discovery: molecular therapeutics and target identification, Volume II
por: Gunosewoyo, Hendra, et al.
Publicado: (2023)

Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.
por: Siemann, D. W.
Publicado: (1982)

Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice.
por: Lee, F. Y., et al.
Publicado: (1983)

Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets
por: Alsayed, Shahinda S. R., et al.
Publicado: (2023)

Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies
por: Odia, Yazmin, et al.
Publicado: (2022)

Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma
por: Hsu, Andrew, et al.
Publicado: (2022)

Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
por: Lee, F. Y., et al.
Publicado: (1985)

Misonidazole and CCNU: further evidence for a pharmacokinetic mechanism of chemosensitization and therapeutic gain.
por: Lee, F. Y., et al.
Publicado: (1984)

Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review
por: Hafazalla, Karim, et al.
Publicado: (2018)

Effects of nandrolone decanoate on the toxicity and anti-tumour action of CCNU and FU in murine tumours.
por: Bibby, M. C., et al.
Publicado: (1981)

Structure/activity relationships for the enhancement by electron-affinic drugs of the anti-tumour effect of CCNU.
por: Workman, P., et al.
Publicado: (1982)

Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis
por: Jeffers, Ann, et al.
Publicado: (2019)

Identification of a subpopulation of MeCCNU resistant cells in previously untreated Lewis lung tumours.
por: Stephens, T. C., et al.
Publicado: (1984)

Emergence of nitrosourea resistant sublines of Lewis lung tumour following MeCCNU treatment in vivo.
por: Stephens, T. C., et al.
Publicado: (1986)

Is CCNU (lomustine) valuable for treatment of cutaneous epitheliotropic lymphoma in dogs? A critically appraised topic
por: Laprais, Aurore, et al.
Publicado: (2017)

Archibald Inglis
Publicado: (1889)

Mallet-ing
Publicado: (1860)

Inge Borghuis
por: Kiers, Bart
Publicado: (2020)

Indoleamides are active against drug-resistant Mycobacterium tuberculosis
por: Lun, Shichun, et al.
Publicado: (2013)

Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM)
por: Xu, Xiang, et al.
Publicado: (2014)

Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU.
por: Twentyman, P., et al.
Publicado: (1982)

The Many Spaces of uPAR: Delivery of Theranostic Agents and Nanobins to Multiple Tumor Compartments through a Single Target
por: O'Halloran, Thomas V., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_b7q1p40tmgvc6fp88cduf1d3t4